Scil Technology Announces Update on MiraXion®

MARTINSRIED, Germany, March 1, 2005 – Scil Technology, a biopharmaceutical company focused on the development of dental and orthopaedic tissue regeneration products, has announced an update on MiraXion®, a new medicinal product to which Scil Technology holds marketing rights in Europe for the treatment of Huntington's disease.  Amarin Neuroscience Ltd, one of Scil Technology´s licensors, is preparing to commence two phase III trials with MiraXion® late in the second quarter of this year.

MiraXion® is a semi-synthetic, highly purified derivative of the n-3 fatty acid eicosapentaenoate (EPA). The mechanism of action is believed to involve the stabilisation of mitochondrial integrity in compromised neurons, thereby preventing or slowing progression from neuronal dysfunction to cell death. The product is designated as an Orphan Medicinal Product by both the FDA and the EMEA.

Amarin intends to utilize the data from these trials to support an application for marketing approval to the U.S. and E.U. regulatory authorities. In Europe, prior to its acquisition by Amarin, Laxdale submitted a marketing approval application based upon the initial phase III study. However, Amarin now plans to re-submit when data from the two planned phase III trials is available. MiraXion® has been granted Fast Track designation by the U.S. Food and Drug Administration and has Orphan Drug status in the U.S. and E.U. The trials are scheduled to commence mid-2005 and last for six months each consecutively.

Scil Technology holds the marketing rights to MiraXion® in certain European countries such as Germany, France, BeNeLux, Austria, Switzerland, Poland, Czech Republic, Slovakia and Turkey.

Further information on MiraXion® can be found here: http://www.amarincorp.com/news.cfm

About Scil Technology GmbH

Scil Technology is a private biopharmaceutical development company focused on dental and orthopaedic tissue regeneration with a particular emphasis on bone and cartilage repair. The Company’s lead therapeutic candidates are based on recombinant, highly specific human growth factors. These are combined with biodegradable biomaterials to generate local application forms. Scil Technology’s pipeline for dentistry includes products that are targeted at periodontal disease, dental implantology and maxillofacial surgery. Orthopaedic products are developed for spinal fusion, bone trauma, joint cartilage defects and osteoarthritis. Scil Technology has emerged from the Scil Group and is located in the biotechnology cluster in Martinsried, Germany.

For more information please visit: http://www.scil.com

About Amarin Corporation

Amarin Corporation plc is a neuroscience company focused on the development and commercialization of novel drugs for the treatment of central nervous system disorders. MiraXion®, Amarin's lead development compound, is in phase III development for Huntington's disease and in phase II development for treatment-unresponsive depression. Amarin Neuroscience Ltd has licensed the rights to Scil Technology GmbH to market exclusively its new product MiraXion® in Germany, France, Austria and BeNeLux.

For press releases and other corporate information, please visit: http://www.amarincorp.com.

About Scarista Ltd.

Scarista Ltd. (Isle of Man, UK) is a pharmaceutical company that owns intellectual property on central nervous system disorders and diabetes. Scarista has licensed the rights to Scil Technology GmbH to market exclusively its new product MiraXion® in Switzerland, Poland, Hungary, the Czech Republic, Slovakia and Turkey.

Contacts

Media relations:

Sue Charles, MA, MBA, CEO
Northbank Communications
t : +44 (0) 20 7886 8152
e: s.charles@northbankcommunications.com

Douglas Pretsell, Ph.D., Senior Account Manager
Northbank Communications
t : +44 (0) 20 7886 8158
e:  d.pretsell@northbankcommunications.com

At Scil Technology:

Dr Irina Staatz-Granzer, Managing Director
Scil Technology GmbH
t: +49 (0)89 85651824
e: irina.staatz@scil.com

At Amarin Corporation plc:

Rick Steward, Chief Executive Officer
Alan Cooke, Chief Financial Officer
Amarin Corporation plc
t: +44 (0) 20 7907 2442
e: investor.relations@amarincorp.com

Notes for Editors

Huntington’s Disease

Huntington´s disease, previously known as Huntington's chorea, is a rare, hereditary neurodegenerative brain disease. It is characterised by a combination of movement abnormalities and personality changes progressing to mental dementia. Onset of the disease is usually in the fourth decade of life but may also occasionally occur in early childhood or late life. The symptoms consist of choreatic movement disorders in addition to a progressive loss of control of the fine motor movements. In the early stages of the disease, activities such as tying shoe laces or holding a glass without spilling the contents become difficult. As the disease progress, there are organic personality changes and, in the final stage of the disease, there is a profound dementia.